Free Trial

Amylyx Pharmaceuticals (AMLX) Competitors

Amylyx Pharmaceuticals logo
$8.24 -0.06 (-0.69%)
As of 02:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AMLX vs. CRNX, MOR, ALVO, RXRX, MIRM, CPRX, NAMS, GMTX, RARE, and AMRX

Should you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Recursion Pharmaceuticals (RXRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Ultragenyx Pharmaceutical (RARE), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

Amylyx Pharmaceuticals vs. Its Competitors

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Crinetics Pharmaceuticals' return on equity of -30.95% beat Amylyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Crinetics PharmaceuticalsN/A -30.95% -28.12%
Amylyx Pharmaceuticals N/A -77.21%-63.84%

Crinetics Pharmaceuticals currently has a consensus price target of $69.50, indicating a potential upside of 125.51%. Amylyx Pharmaceuticals has a consensus price target of $11.75, indicating a potential upside of 42.55%. Given Crinetics Pharmaceuticals' higher possible upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crinetics Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Amylyx Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
3.00

Crinetics Pharmaceuticals has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$1.04M2,774.60-$298.41M-$3.82-8.07
Amylyx Pharmaceuticals$87.37M8.41-$301.74M-$3.11-2.65

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Crinetics Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500.

In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 8 mentions for Crinetics Pharmaceuticals and 5 mentions for Amylyx Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.48 beat Amylyx Pharmaceuticals' score of 0.95 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Crinetics Pharmaceuticals
6 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amylyx Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Crinetics Pharmaceuticals beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMLX vs. The Competition

MetricAmylyx PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$735.49M$2.76B$5.71B$9.51B
Dividend YieldN/A1.78%4.60%3.99%
P/E Ratio-2.659.0628.0720.02
Price / Sales8.41744.11459.47103.02
Price / CashN/A166.2336.5558.97
Price / Book3.435.188.615.88
Net Income-$301.74M$30.99M$3.24B$258.50M
7 Day Performance-1.16%7.26%3.83%2.03%
1 Month Performance31.68%15.66%10.40%12.52%
1 Year Performance329.32%-1.06%34.13%19.07%

Amylyx Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMLX
Amylyx Pharmaceuticals
3.309 of 5 stars
$8.24
-0.7%
$11.75
+42.5%
+332.3%$735.49M$87.37M-2.65200
CRNX
Crinetics Pharmaceuticals
3.6781 of 5 stars
$30.95
-0.5%
$69.50
+124.6%
-43.1%$2.90B$1.04M-8.10210Positive News
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
ALVO
Alvotech
2.8352 of 5 stars
$8.64
+0.1%
$16.00
+85.2%
-21.0%$2.60B$491.98M23.351,032
RXRX
Recursion Pharmaceuticals
1.4367 of 5 stars
$6.40
+9.6%
$7.00
+9.4%
-19.8%$2.60B$58.84M-3.62400High Trading Volume
MIRM
Mirum Pharmaceuticals
3.8551 of 5 stars
$51.95
+0.0%
$65.50
+26.1%
+33.5%$2.57B$336.89M-32.27140Positive News
CPRX
Catalyst Pharmaceuticals
4.9232 of 5 stars
$21.01
-0.1%
$32.83
+56.3%
+20.0%$2.56B$491.73M13.3880News Coverage
Positive News
Analyst Revision
NAMS
NewAmsterdam Pharma
3.7852 of 5 stars
$22.56
+1.6%
$41.30
+83.1%
+23.8%$2.53B$45.56M-12.004
GMTX
Gemini Therapeutics
N/A$57.77
0.0%
N/A+32.1%$2.50BN/A-57.7730High Trading Volume
RARE
Ultragenyx Pharmaceutical
4.35 of 5 stars
$26.39
+0.3%
$83.64
+216.9%
-39.5%$2.49B$560.23M-4.491,294Upcoming Earnings
Gap Down
High Trading Volume
AMRX
Amneal Pharmaceuticals
3.1369 of 5 stars
$7.91
-0.8%
$11.60
+46.6%
+8.0%$2.48B$2.79B-197.708,100

Related Companies and Tools


This page (NASDAQ:AMLX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners